Best Health is a Moroccan specialist in the distribution and instalment of medical equipment for hospitals and clinics in Morocco and Tunisia, and portfolio company of Amethis Maghreb Fund I. In July 2020, the Group finalized the acquisition of Mabiotech, the 3rd player in the distribution of in-vitro diagnostic devices and reagents for public and private medical laboratories.
Mabiotech has a comprehensive line of products covering the industry’s most important specialties, including immunology, biochemistry, hematology and microbiology. Thanks to its large product portfolio, its exclusive and longstanding relationships with top-tier suppliers such as Beckman Coulters and its reputable customer service, Mabiotech is now #3 in the market. The company benefited from the Covid-19 context as it distributes tests and is a key supplier of testing equipment.
Mabiotech has significant growth perspectives as the in vitro diagnostics market should benefit from the progress of the 2025 Health Plan in terms of universal medical coverage, health spending and hospital infrastructure (establishment of new medical biology laboratories in public hospitals). For Mabiotech, this acquisition represents an opportunity to become part of a well-established player in the market, expanding its Moroccan and African customer portfolio and benefiting from the Best Health network. In addition, this transaction allows Mabiotech to benefit from the pooling of the group’s technical and financial support, opening the door to greater exposure.
With this operation, Best Health enhances its market positioning as it is now able to serve its clients with a full range of products offering, becoming one of a kind player in its market. These complementary activities will also result in significant commercial and operational synergies, and, this transaction will have a positive impact on profitability and cash flow profile.